CLAIMS

1. A mutant TGFβ polypeptide that antagonizes the activity of the TGFβ1, TGFβ2 and TGFβ3 ligands mediated by the ALK5 receptor, characterized by comprising at least one mutation in one of the amino acid residues selected from the group consisting of W30, W32, L101, I51 or L51, Q67 and Y6 wherein said polypeptide has an amino acid sequence of any one of SEQ ID Nos: 1-73.

2. A mutant TGFβ polypeptide that antagonizes the activity of the TGFβ1, TGFβ2 and TGFβ3 ligands mediated by the ALK5 receptor, characterized by comprising an amino acid substitution mutation in the amino acid residues W30, L101 and I51 wherein said polypetide has an amino acid sequence of SEQ ID No. 74.

3. The polypeptide according to claims 1 to 2 characterized by more than 90% homology with the sequence of TGFβ1, TGFβ2 and TGFβ3 ligands.

4. The polypeptide according to claims 1 to 3 coupled to a fragment of human IgG1 comprising the mutations ala234 and ala235 in Cγ2 domain.

5. A pharmaceutical composition comprising;

   at least one polypeptide of claims 1-4 in a range between 50ng/mL-10μg/mL; and
   a pharmaceutically suitable vehicle.

6. A pharmaceutical composition according to claim 5 comprising;
   a therapeutically effective amount of a mixture of the polypeptides of claims 1-4 and
   a pharmaceutically suitable vehicle.

7. Use of the polypeptide of any of claims 1 to 4 in the manufacture of a medicament for the treatment of cancer.